Looking for predictive markers in breast cancer

Affiliations

¹ Department of Medical and Biological Sciences, University of Udine, Italy; Department of Oncology, University Hospital of Udine, Italy. Electronic address: bonottomarta@gmail.com.
² Department of Medical and Biological Sciences, University of Udine, Italy; Department of Oncology, University Hospital of Udine, Italy.

Comment

Marta Bonotto et al. Lancet Oncol. 2015 Jan.

. 2015 Jan;16(1):e1.

doi: 10.1016/S1470-2045(14)71107-6. Epub 2014 Dec 29.

¹ Department of Medical and Biological Sciences, University of Udine, Italy; Department of Oncology, University Hospital of Udine, Italy. Electronic address: bonottomarta@gmail.com.
² Department of Medical and Biological Sciences, University of Udine, Italy; Department of Oncology, University Hospital of Udine, Italy.

No abstract available

Comment on

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, Gupta V, Costa R, Srock S, de Ducla S, Freudensprung U, Mustacchi G. Gligorov J, et al. Lancet Oncol. 2014 Nov;15(12):1351-60. doi: 10.1016/S1470-2045(14)70444-9. Epub 2014 Sep 28. Lancet Oncol. 2014. PMID: 25273343 Clinical Trial.